Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Sponsor: University of Colorado, Denver
Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

Assess the safety and efficacy of oral nicotinamide riboside for 3 months vs. placebo for decreasing aortic stiffness and SBP in patients with stage III and IV CKD. Hypothesize that treatment will reduce CFPWV and SBP, as related to increases in systemic NAD+ bioavailability and reductions in oxidative stress, and inflammation.

Study Design

Randomized, double blind, placebo controlled, parallel assignment

Dose

500mg 2x a day

Length of Intervention

3 months

Intrinsic Capacity

Vitality

Status

Recruiting

Condition or Disease 

Vascular Diseases
Kidney Disease
Blood Pressure
Oxidative Stress

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Vitality, RecruitingANAD Staff